Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma.

× No keyword cloud information.

15 in total

1. Idiopathic thrombocytopenic purpura and autoimmune neutropenia induced by prolonged use of nivolumab in Hodgkin's lymphoma.

Authors: A Bulbul; A Mustafa; S Chouial; S Rashad
Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976

Review 2. Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.

Authors: Arnab Ghosh; Ioannis Politikos; Miguel-Angel Perales
Journal: Curr Opin Oncol Date: 2017-11 Impact factor: 3.645

3. High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma.

Authors: Zachary Wright; Alexander Brown
Journal: Blood Adv Date: 2017-07-17

4. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab.

Authors: Samer Tabchi; Xiaoduan Weng; Normand Blais
Journal: Lung Cancer Date: 2016-07-01 Impact factor: 5.705

5. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.

Authors: Eric Smith; Sean M Devlin; Satyajit Kosuri; Evelyn Orlando; Heather Landau; Alex M Lesokhin; David J Chung; Hani Hassoun; Nikoletta Lendvai; Ola Landgren; Sergio Giralt; Ajai Chari; Sundar Jagannath; Guenther Koehne
Journal: Biol Blood Marrow Transplant Date: 2015-08-30 Impact factor: 5.742

6. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).

Authors: Mojtaba Akhtari; Edmund K Waller; David L Jaye; David H Lawson; Ramy Ibrahim; Nicholas E Papadopoulos; Martha L Arellano
Journal: J Immunother Date: 2009-04 Impact factor: 4.456

7. Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab.

Authors: Ilit Turgeman; Mira Wollner; Gamal Hassoun; Lilach Bonstein; Gil Bar-Sela
Journal: Anticancer Drugs Date: 2017-08 Impact factor: 2.248

Review 8. Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports.

Authors: Noha Abdel-Wahab; Mohsin Shah; Maria E Suarez-Almazor
Journal: PLoS One Date: 2016-07-29 Impact factor: 3.240

9. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.

Authors: C Cho; M Hsu; P Barba; M A Maloy; S T Avecilla; J N Barker; H Castro-Malaspina; S A Giralt; A A Jakubowski; G Koehne; R C Meagher; R J O'Reilly; E B Papadopoulos; D M Ponce; R Tamari; M R M van den Brink; J W Young; S M Devlin; M-A Perales
Journal: Bone Marrow Transplant Date: 2017-10-09 Impact factor: 5.483

Review 10. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.

Authors: Marianne Davies; Emily A Duffield
Journal: Immunotargets Ther Date: 2017-08-24

2 in total

Review 1. Post-hematopoietic stem cell transplantation relapse: Role of checkpoint inhibitors.

Authors: Elham Roshandel; Farzaneh Tavakoli; Sayeh Parkhideh; Sedigheh Sadat Akhlaghi; Maria Tavakoli Ardakani; Masoud Soleimani
Journal: Health Sci Rep Date: 2022-03-08

2. Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.

Authors: J Boegeholz; C S Brueggen; C Pauli; F Dimitriou; E Haralambieva; R Dummer; M G Manz; C C Widmer
Journal: BMC Cancer Date: 2020-04-14 Impact factor: 4.430

2 in total